← Back to companies
Oncolytics Biotech
39+ employees
Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments.
Open Positions at Oncolytics Biotech (0 Jobs)
No open positions at the moment.
Browse All JobsReady to start your space career at Oncolytics Biotech?
